Treatment of Melanoma

Hofmann, Maja; Sterry, Wolfram; Schwartz, Robert A.

doi:10.1002/9780470696347.ch31

Skin Cancer 2008

DOI: 10.1002/9780470696347.ch31

|View full text |Cite

Treatment of Melanoma

Maja Hofmann¹,

Wolfram Sterry²,

Robert A. Schwartz³

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 235 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basic principle in the management of primary cutaneous malignant melanoma has remained the wide surgical excision for decades [1][2][3][4]. Complete excision of the primary skin lesion along with removal of adjacent subcutaneous fatty tissue with an appropriate margin of normal tissue according to Breslow thickness is considered the standard approach [5].…”

mentioning

confidence: 99%

Recurrence after sentinel lymph node biopsy in cutaneous melanoma: a single-center experience in Slovak patients

Sabol

Rekeň

Sabolova

et al. 2019

neo

View full text Add to dashboard Cite

The standard approach in the management of cutaneous malignant melanoma is considered to be a complete excision of the primary lesion with an appropriate margin of the normal tissue according to Breslow thickness. Usually sentinel lymph node biopsy (SLNB) can help to determine the nodal status, and thus improve the accuracy of staging of the disease. However, the role of SLNB in melanoma treatment remains controversial. NCCN guidelines strongly support routine performance of therapeutic lymphadenectomy in all melanoma patients with clinically positive nodes without radiographic evidence of distant metastases. Patients with positive SLNB should have had completion lymph node dissection (CLND) for regional disease control. Between 2012 and 2016, 168 consecutive patients underwent surgery for primary cutaneous malignant melanoma at St. Elisabeth Cancer Institute in Bratislava. The indication for SLNB and the procedure was made according to international guidelines. In this retrospective study, a cohort of 78 patients was analyzed (35 women and 43 men). Inclusion criteria comprised patients with cutaneous melanoma with no evidence of distant metastases or clinical lymphadenopathy. SLNB comprised a dual labelling method (Tc-99m Nanocolloid/blue dye) in a one-day protocol. Median follow-up was 657 days. The primary composite outcome was the time to the first disease-related event (death, reintervention, worsening of symptoms). Primary outcome measures were overall (diseasespecific) and disease-free survival. The overall identification rate of SLN in melanoma patients by dual labelling method was 98.5%. All patients with positive SLNB on frozen section underwent complete regional lymphadenectomy. Using multivariable analysis Breslow thickness of the lesion (p=0.00004, HR 4.03 on logarithmic scale) was identified as the strongest independent predictor of the disease-free survival (DFS) and male gender was significant predictor of DFS. An increase in tumor thickness was associated with significantly higher risk of an event. Neither SLN positivity nor initial S-100 level proved to be significant predictors of the event at the 0.05 level of probability. Multidisciplinary approach represents the gold standard of care for melanoma patients and surgery remains the best option for most localized cases. Although the usefulness of SLNB procedure has been questioned, it provides an excellent staging method, moreover, it can identify high-risk patients. The routine use of completion lymphadenectomy after a positive SLNB is still controversial. It is not clear whether CLND following a positive SLN biopsy improves survival but it could provide regional disease control.

show abstract

mentioning

confidence: 99%

Recurrence after sentinel lymph node biopsy in cutaneous melanoma: a single-center experience in Slovak patients

Sabol

Rekeň

Sabolova

et al. 2019

neo

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Treatment of Melanoma

Cited by 1 publication

References 235 publications

Recurrence after sentinel lymph node biopsy in cutaneous melanoma: a single-center experience in Slovak patients

Recurrence after sentinel lymph node biopsy in cutaneous melanoma: a single-center experience in Slovak patients

Contact Info

Product

Resources

About